EGFR and neoplasm: Given our findings, it may be of high benefit for the physicians and oncologists to take into consideration that the risk of death and/or the risk of distant metastasis may be predicted by evaluating the EGFR status of the patients in correlation with other clinicopathological parameters like the tumor stage, tumor grade, lymph node status, and others.